Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cell-penetrating antibody therapeutics - LA Cell

Next Previous
X
Search
Drug Profile

Research programme: cell-penetrating antibody therapeutics - LA Cell

Alternative Names: Intracellular Targeting Antibodies -LA Cell; iTAbs; KRASG12D iTAb; Mutant KRAS iTAb; STAT3 iTAb

Latest Information Update: 28 Apr 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LA Cell
  • Developer City of Hope National Medical Center; LA Cell
  • Class Monoclonal antibodies
  • Mechanism of Action Protein modulators; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Apr 2021 No recent reports of development identified for preclinical development in Cancer in USA (IV)
  • 19 Apr 2018 Sorrento Therapeutics has patents pending for the intracellular targeting antibody (iTAb) technology (LA Cell) for targeting intracellular targets
  • 22 Mar 2017 Preclinical trials in Cancer in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top